News | January 06, 2022
Aurobindo Pharma rolls out Molnaflu in India
The brand is now available pan-India through their distribution partner
The brand is now available pan-India through their distribution partner
The company has also started working with a large pharma company on the API supply of a recently launched animal and human health product
Key takeaways of recent quarter & conference call highlights
They enter into exclusive negotiations in a new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
The Bidar API manufacturing facility of Sai Life Sciences has been on a path of significant expansion with its production capacity growing from 200KL in 2017 to 450KL
Enoxaparin Sodium Injection, USP is used for prophylaxis of Deep Vein Thrombosis (DVT) in patients undergoing abdominal, hip or knee replacement surgery, and also for the treatment of acute DVT
Anti-malaria API facility will be operational in 15-18 months
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
Ranitidine Hydrochloride is an important product for Solara and is manufactured at its Cuddalore site
Subscribe To Our Newsletter & Stay Updated
